{"entity":{"id":"nct06140836","kind":"trial","name":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","aka":["TRIDENT-3"],"tldr":"A phase 3 trial of Repotrectinib and Crizotinib in non-small-cell lung cancer, run by Bristol-Myers Squibb, active and no longer recruiting.","summary":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) is a phase 3 interventional study registered as NCT06140836 by Bristol-Myers Squibb, with 190 participants enrolled, started 2023-12-21 and due to reach its primary completion in 2026-03-13. Interventions recorded: Repotrectinib and Crizotinib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06140836","url":"https://clinicaltrials.gov/study/NCT06140836"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","ros1-positive-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["repotrectinib","crizotinib"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06140836","phase":"3","setting":"Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","sponsor":"Bristol-Myers Squibb","started":"2023-12-21","startedType":"actual","enrolled":190,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06140836/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/"},{"id":"repotrectinib","kind":"drug","name":"Repotrectinib","route":"/drugs/repotrectinib/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}